Strategies of treatment for febrile neutropenia

Japanese Journal of Cancer and Chemotherapy

Volumn 40, Issue 6, 2013, Pages 688-692

  Terui, Yasuhito ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Febrile neutropenia; Guideline; Treatment strategy

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT;

ANTIBIOTIC THERAPY; ARTICLE; FEBRILE NEUTROPENIA; HEALTH CARE PLANNING; HUMAN; PRACTICE GUIDELINE;

EID: 84882767653     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Klastersky J: Concept of empiric therapy with antibiotic combinations. Indications and limits. Am J Med 80(5C):2-12, 1986.
2. Schimpff S, Satterlee W, Young VM, et al: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284(19):1061-1065, 1971.
3. Bow EJ, Rotstein C, Noskin GA, et al: A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43(4):447-459, 2006. (Pubitemid 44157153)
4. Tamura K, Matsuoka H, Tsukada J, et al: Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin+aminoglycosides: comparative study. Am J Hematol 71(4):248-255, 2002. (Pubitemid 35396940)
5. Cherif H, Björkholm M, Engervall P, et al: A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 36(8):593-600, 2004. (Pubitemid 39247980)
6. Feld R, DePauw B, Berman S, et al: Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 18(21):3690-3698, 2000.
7. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56-93, 2011.
8. Mustafa MM, Carlson L, Tkaczewski I, et al: Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 20(3):362-369, 2011.
9. Bauduer F, Cousin T, Boulat O, et al: A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma 42(3):379-386, 2001. (Pubitemid 32725593)
10. Ichikawa M, Suzuki D, Ohshima J, et al: Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. Pediatr Blood Cancer 57(7):1159-1162, 2011.
11. Sato T, Kobayashi R, Yasuda K, et al: A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 51(6):774-777, 2008.
12. Nakagawa Y, Suzuki K, Hirose T, et al: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother 17(1):58-67, 2011.
13. Kwon KT, Cheong HS, Rhee JY, et al: Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol 38(1):49-55, 2008. (Pubitemid 351248120)
14. Antoniadou A and Giamarellou H: Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 21(4):1055-1090, 2007. (Pubitemid 350166841)
15. Rolston KV, Bodey GP and Safdar A: Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 45(2):228-233, 2007. (Pubitemid 47041015)
16. Freifeld A, Marchigiani D, Walsh T, et al: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341(5):305-311, 1999. (Pubitemid 29350300)
17. Kern WV, Cometta A, De Bock R, et al: Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341(5):312-318, 1999. (Pubitemid 29350301)
18. Niho S, Ohe Y, Goto K, et al: Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 34(2):69-73, 2004. (Pubitemid 43115321)
19. Mullen CA, Petropoulos D, Roberts WM, et al: Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86(1):126-134, 1999. (Pubitemid 29293385)
20. Mizuno T, Katsumata N, Mukai H, et al: The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 15(3):287-291, 2007. (Pubitemid 46295204)
21. Cornely OA, Wicke T, Seifert H, et al: Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 79(1):74-78, 2004. (Pubitemid 38182205)
22. Bellesso M, Costa SF, Pracchia LF, et al: Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies. Ann Hematol 90(4):455-462, 2011.
23. Sebban C, Dussart S, Fuhrmann C, et al: Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16(9):1017-1023, 2008.
24. NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infections (Version 1.2011). http://www.nccn.org/ professionals/physician-gls/pdf/infections.pdf
25. Jaksic B, Martinelli G, Perez-Oteyza J, et al: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42(5):597-607, 2006. (Pubitemid 43271371)
26. Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 38(3):547-557, 1994. (Pubitemid 24072247)
27. American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388-416, 2005.
28. Teuffel O, Ethier MC, Alibhai SM, et al: Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22(11):2358-2365, 2011.
29. Elting LS, Lu C, Escalante CP, et al: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26(4):606-611, 2008. (Pubitemid 351264355)
30. Lehrnbecher T, Stanescu A and Kühl J: Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 30(1):17-21, 2002. (Pubitemid 34146407)
31. Jones GR, Konsler GK, Dunaway RP, et al: Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 124(5 Pt 1):703-708, 1994. (Pubitemid 24161457)
32. Raad II, Escalante C, Hachem RY, et al: Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98(5):1039-1047, 2003. (Pubitemid 37022106)
33. Marra CA, Frighetto L, Quaia CB, et al: A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 20(8):931-940, 2000. (Pubitemid 30659790)
34. Slobbe L, Waal L, Jongman LR, et al: Three-day treatment with imipenem for unexplained fever during prolonged neutropenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer 45(16):2810-2817, 2009.
35. Cometta A, Kern WV, De Bock R, et al: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37(3):382-389, 2003. (Pubitemid 36976496)